30.06.2014 Views

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

INDEX<br />

Topical anti-inflammatory therapy,<br />

respiratory disease 462–463<br />

Topical dermatological<br />

therapy 546–556<br />

antimicrobials 152, 552–553<br />

creams, emulsions and<br />

ointments 554<br />

glucocorticoids 263<br />

otitis externa 153, 554–556<br />

pathophysiology 546<br />

practical tips 546–550<br />

shampoos, moisturizers and<br />

conditioners 547, 550–554<br />

Topical ear medications 548<br />

application 549–550<br />

otitis externa 153, 554–556<br />

Topical ophthalmic therapy 557–558,<br />

558<br />

anesthetics 558, 572<br />

corticosteroids 263, 558, 560–561<br />

glaucoma 558, 570–571<br />

glycerin 572<br />

NSAIDs 558, 563<br />

Total intravenous anesthesia<br />

(TIVA) 95, 316<br />

Toxicity 35<br />

antibacterials 152<br />

antiparasitics 199–200, 200–204,<br />

556<br />

cancer chemotherapy 333–334<br />

new drugs/new chemical entities<br />

(NCEs) 21<br />

organophosphates 233–234<br />

paracetamol (acetaminophen) 306<br />

see also Digitalis toxicity;<br />

Hepatotoxicity; Renal toxicity<br />

Toxoplasmosis, antibacterial drug<br />

choice 153<br />

Tramadol 327–328<br />

Tranquilizers<br />

vs sedatives 113<br />

see also Sedatives<br />

Transdermal administration 30<br />

fentanyl patches 317–318<br />

thiamazole 502<br />

Transfereases 32<br />

Transmembrane carriers 29 (see also<br />

P-gp)<br />

Transport across membranes 27–29<br />

Transport proteins 9<br />

Travaprost 571<br />

Tri-iodothyronine 499, 508<br />

Triamterene 394, 395<br />

Triazines 239<br />

Triazolam 135<br />

Triazoles 189<br />

new 193–194<br />

pharmacokinetics 190<br />

Tricin ointment 564<br />

Triclosan 553<br />

Tricyclic antidepressants (TCAs) 9, 71,<br />

136–138<br />

and SSRIs interaction 140<br />

Trifluralin 204<br />

Trifluridine 568<br />

Trilostane 520–521<br />

Trimethoprim 151, 179, 180, 201<br />

antiprotozoal dosage 239<br />

Trimethoprim-sulfonamide 179, 180<br />

and imipenem interaction 168<br />

Tropicamide 569<br />

Tropisetron 475<br />

Trypan blue 238, 244<br />

Tubulin-binding agents 335–340<br />

‘Two neurone’ rule of ANS 59<br />

Tylosin 178<br />

Tyrosine kinase-associated receptors 9<br />

U<br />

Ulcerative stomatitis, antibacterial drug<br />

choice 153<br />

Ultralente insulin 511–512<br />

Unfractionated heparin 453–455<br />

United Kingdom, reporting adverse<br />

drug reactions (ADRs) 57<br />

United States of America, reporting<br />

adverse drug reactions<br />

(ADRs) 57<br />

Ureidopenicillins 163<br />

Urinary retention, opioid<br />

analgesics 315<br />

Urinary tract infection, antibacterial<br />

drug choice 153<br />

Urine glucose test 168<br />

Urine pH 33<br />

drug interactions mechanisms 17<br />

Urine spraying in cats 145–146<br />

Urogenital parasites 252<br />

Ursodeoxycholic acid<br />

(ursodiol) 491–492<br />

University of Wisconsin-Madison<br />

chemotherapy protocol 365<br />

V<br />

Vaccines<br />

adverse drug reactions (ADRs) 46,<br />

50, 54<br />

immune response genes 54<br />

Valproic acid 9, 377<br />

Vancomycin 169<br />

Vapour pressure, inhalational<br />

anesthesia 84–85<br />

Vascular actions of acetylcholine<br />

(ACh) 65<br />

Vasoactive intestinal peptide (VIP) 64<br />

Vasodilators 402–404<br />

with additional properties 411–412<br />

pimobendan 399<br />

pure 404–411<br />

Vecuronium bromide 75–77<br />

Vedaprofen 293, 303<br />

Ventricular arrhythmias 426, 427<br />

Ventricular relaxation see Positive<br />

lusitropic agents<br />

Verapamil 443–444<br />

adverse effects 50, 51, 444<br />

clinical applications 427, 443<br />

drug efflux inhibition 211<br />

drug interactions 275, 322, 333,<br />

444, 479<br />

formulations and dose rates 427,<br />

443–444<br />

inhibition of drug metabolising<br />

enzymes 17, 33<br />

mechanism of action 9, 443<br />

pharmacokinetics 11, 444<br />

Veterinarian–client–patient relationship<br />

(VCPR) 24–25<br />

Vinblastine 333, 336, 337–338<br />

Vincristine 333, 336, 336–337<br />

Vinorelbine 338<br />

Vitamin D 503–504<br />

oral preparations 507–508<br />

receptor 9<br />

Volume of distribution (V) 2, 3, 31,<br />

32, 34, 35, 39–40<br />

Vomit center 469<br />

Vomiting<br />

cisplatin toxicity 356<br />

opioid analgesics 314, 321<br />

Voriconazole 189, 193<br />

adverse effects 191<br />

pharmacokinetics 190<br />

W<br />

Warfarin 455–456<br />

Websites 11<br />

regulatory agencies 11, 12<br />

White soft paraffin 486<br />

Wolf–Chaikoff effect 503<br />

Wounds, antibacterial drug choice<br />

153<br />

X<br />

Xanthine derivative glial cell<br />

modulators 146–147<br />

Xylazine 71, 120–124<br />

atipamezole as antidote to 74<br />

and nicergoline interaction<br />

144<br />

Y<br />

Yohimbine 124<br />

adrenoceptor antagonist 71<br />

amitraz antidote 224<br />

Z<br />

Zafirlukast 467–468<br />

Zero-order process 33–34<br />

Zileuton 467–468<br />

Zinc 494<br />

Zolazepam 118–120<br />

Zonisamide 368, 378–379<br />

589

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!